New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:37 EDTCGIXCancer Genetics adds additional kidney cancer patent to portfolio
Cancer Genetics announced that the U.S. Patent and Trademark Office has allowed its patent claims related to the company's proprietary methods for detecting the subtype of renal cortical neoplasm present in a patient sample. The patent application is expected to obtain an issued patent number during 2Q14. This latest patent builds on the intellectual property portfolio the company has already gained for kidney cancer diagnostics. New data further validating CGI's UroGenRA Kidney test will be presented on March 3 at the annual U.S. & Canadian Academy of Pathology meeting. In the study, 191 pathology specimens from renal cancer patients were analyzed using CGI's proprietary genomic microarray test, which enables accurate classification of kidney cancer among the four major subtypes and predicts whether the cancer is benign or malignant. The test has been validated to work across sample types ranging from fine-needle aspirate to paraffin-embedded and formalin-fixed tissue, making it widely usable for both new cases as well as cases that are not diagnosable using traditional methods
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:09 EDTCGIXCancer Genetics granted patent for FHACT
Subscribe for More Information
October 15, 2014
07:32 EDTCGIXRedChip Companies to hold a virtual conference
Subscribe for More Information
October 13, 2014
07:52 EDTCGIXCancer Genetics partners with Columbia University oncology researchers
Cancer Genetics has entered into a research collaboration with Columbia University's Azra Raza, MD, director of the MDS Center and assistant professor of medicine at Columbia University Medical Center, and Siddhartha Mukherjee, MD, PhD, assistant professor of medicine at CUMC, to identify more accurate diagnostic and prognostic markers for myelodysplastic syndromes, as well as novel therapies to target this class of bone marrow cancers. The ultimate goal of the collaboration is to develop personalized therapy for MDS patients and to enable accurate prediction of future treatment needs before patients become resistant to their current therapy or before their MDS progresses to the more aggressive acute myeloid leukemia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use